Introduction

Innovative treatment in the prevention and treatment of childhood hemolytic-uremic syndrome (HUS) by using the drug NAB815, a non-toxic polymyxin b derivative, at non-bactericidal concentrations in patients infected with Shiga toxin-producing Escherichia coli strains.

 

Technical features

Currently, there are no specific treatments available for hemolytic-uremic syndrome; patients receive supportive therapy. The use of NAB815 is intended to prevent hemolytic-uremic syndrome by interacting with Shiga toxin 2 during infection with Shiga toxin-producing Escherichia coli strains, without having bactericidal/bacteriostatic effects.

Possible Applications

• Pharmaceutical industry.

Advantages

• Reduction in the need for kidney transplantation;
• reduction in dialysis treatments;
• reduction in healthcare costs.